Portola Pharmaceuticals Inc Expected to Earn FY2021 Earnings of $5.72 Per Share (PTLA)

Portola Pharmaceuticals Inc (NASDAQ:PTLA) – Equities researchers at Oppenheimer cut their FY2021 earnings per share (EPS) estimates for shares of Portola Pharmaceuticals in a report issued on Wednesday. Oppenheimer analyst J. Olson now anticipates that the biopharmaceutical company will post earnings of $5.72 per share for the year, down from their previous forecast of $5.81. Oppenheimer has a “Buy” rating and a $80.00 price objective on the stock. Oppenheimer also issued estimates for Portola Pharmaceuticals’ FY2022 earnings at $8.04 EPS.

Portola Pharmaceuticals (NASDAQ:PTLA) last issued its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($1.41) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.49) by $0.08. The firm had revenue of $3.83 million for the quarter, compared to analysts’ expectations of $4.71 million. Portola Pharmaceuticals had a negative return on equity of 110.46% and a negative net margin of 938.19%. Portola Pharmaceuticals’s revenue was down 58.9% on a year-over-year basis. During the same quarter last year, the business posted ($1.64) EPS.

A number of other brokerages have also recently weighed in on PTLA. BidaskClub raised Portola Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday, December 21st. ValuEngine raised Portola Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Zacks Investment Research raised Portola Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, January 10th. Goldman Sachs Group began coverage on Portola Pharmaceuticals in a research note on Friday, December 1st. They issued a “buy” rating and a $75.00 price target on the stock. Finally, William Blair reissued a “buy” rating on shares of Portola Pharmaceuticals in a research note on Monday, January 1st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the stock. Portola Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $70.65.

Shares of Portola Pharmaceuticals (NASDAQ:PTLA) traded down $0.22 on Friday, reaching $44.41. The company had a trading volume of 1,288,901 shares, compared to its average volume of 944,111. The stock has a market cap of $2,910.00, a PE ratio of -10.28 and a beta of 1.18. Portola Pharmaceuticals has a 1 year low of $27.12 and a 1 year high of $67.10. The company has a debt-to-equity ratio of 0.24, a current ratio of 8.31 and a quick ratio of 8.31.

In other Portola Pharmaceuticals news, Director Henry Ward Wolff sold 12,000 shares of Portola Pharmaceuticals stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $47.00, for a total transaction of $564,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 5.50% of the company’s stock.

Large investors have recently added to or reduced their stakes in the business. QS Investors LLC purchased a new position in Portola Pharmaceuticals during the 2nd quarter valued at about $147,000. Oppenheimer Asset Management Inc. grew its stake in Portola Pharmaceuticals by 251.2% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 2,862 shares of the biopharmaceutical company’s stock valued at $155,000 after acquiring an additional 2,047 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Portola Pharmaceuticals by 54.9% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,219 shares of the biopharmaceutical company’s stock valued at $157,000 after acquiring an additional 1,141 shares in the last quarter. Canada Pension Plan Investment Board purchased a new position in Portola Pharmaceuticals during the 3rd quarter valued at about $178,000. Finally, Sei Investments Co. purchased a new position in Portola Pharmaceuticals during the 3rd quarter valued at about $217,000. 87.29% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This report was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2018/02/09/portola-pharmaceuticals-inc-expected-to-earn-fy2021-earnings-of-5-72-per-share-ptla.html.

About Portola Pharmaceuticals

Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.

Earnings History and Estimates for Portola Pharmaceuticals (NASDAQ:PTLA)

Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply